Enovis
ENOV · Health Care Equipment
$21.08
2.4%Globus Medical
GMED · Health Care Equipment
$81.41
0.3%The short version
- Globus Medical is the larger business, with $2.9B of revenue in fiscal 2025 against $2.2B for Enovis.
- Globus Medical grew revenue faster (16.7%, against 6.7%).
- Globus Medical kept more of each dollar of sales as operating profit (16.3% operating margin, against −50.0% operating margin).
- Globus Medical turned more of its sales into free cash flow (20.0% FCF margin, against 0.9% FCF margin).
- Globus Medical earned a higher return on the capital invested in it (11.0%, against −26.9%).
| Latest fiscal year | ENOV · FY25 | GMED · FY25 |
|---|---|---|
| Size | ||
| Market cap | $1.2B | $11.2B |
| Revenue | $2.2B | $2.9B |
| Free cash flow | $19.9M | $589M |
| Net income | −$1.2B | $538M |
| Growth | ||
| Revenue growth | 6.7% | 16.7% |
| 5-year growth | 14.9% | 30.1% |
| Share count change | 3.2% | −0.6% |
| Profitability | ||
| Gross margin | 59.8% | 67.4% |
| Operating margin | −50.0% | 16.3% |
| Net margin | −52.7% | 18.3% |
| FCF margin | 0.9% | 20.0% |
| Return on capital | −26.9% | 11.0% |
| Return on equity | −58.5% | 12.3% |
| Balance sheet | ||
| Net debt | $1.3B | −$556M |
| Net debt / EBITDA | 5.7x | −0.7x |
| Dividends and buybacks | $3.5M | $301M |
| Valuation & quality | ||
| P/E | — | 20.9x |
| Piotroski F-score | 4 | 9 |
FY16
ENOV $3.2B
GMED $564M
FY17
ENOV $1.9B
GMED $636M
FY18
ENOV $2.2B
GMED $713M
FY19
ENOV $3.3B
GMED $785M
FY20
ENOV $1.1B
GMED $789M
FY21
ENOV $1.4B
GMED $958M
FY22
ENOV $1.6B
GMED $1.0B
FY23
ENOV $1.7B
GMED $1.6B
FY24
ENOV $2.1B
GMED $2.5B
FY25
ENOV $2.2B
GMED $2.9B
ENOV
GMED
FY16
ENOV 7.4%
GMED 27.3%
FY17
ENOV 7.0%
GMED 25.5%
FY18
ENOV 6.9%
GMED 23.8%
FY19
ENOV 6.1%
GMED 21.9%
FY20
ENOV −5.9%
GMED 14.1%
FY21
ENOV −4.4%
GMED 18.0%
FY22
ENOV −4.6%
GMED 22.3%
FY23
ENOV −3.9%
GMED 8.5%
FY24
ENOV −36.8%
GMED 6.6%
FY25
ENOV −50.0%
GMED 16.3%
ENOV
GMED
FY16
ENOV $184M
GMED $107M
FY17
ENOV $150M
GMED $108M
FY18
ENOV $157M
GMED $122M
FY19
ENOV $5.6M
GMED $101M
FY20
ENOV $187M
GMED $135M
FY21
ENOV $252M
GMED $219M
FY22
ENOV −$161M
GMED $104M
FY23
ENOV $12.8M
GMED $165M
FY24
ENOV −$67.2M
GMED $405M
FY25
ENOV $19.9M
GMED $589M
ENOV
GMED
FY16
ENOV 4.1%
GMED 14.4%
FY17
ENOV 3.0%
GMED 12.7%
FY18
ENOV 3.4%
GMED 16.6%
FY19
ENOV 2.0%
GMED 14.5%
FY20
ENOV −0.9%
GMED 8.3%
FY21
ENOV −0.8%
GMED 12.0%
FY22
ENOV −1.2%
GMED 13.2%
FY23
ENOV −1.4%
GMED 3.7%
FY24
ENOV −15.9%
GMED 3.7%
FY25
ENOV −26.9%
GMED 11.0%
ENOV
GMED
Add another company
Compare up to four at once.
Each company's latest fiscal year; fiscal years end in different months. The best value in each row is highlighted where higher (or lower) is clearly better. Not investment advice.